Roberto De Luca

660 total citations
32 papers, 472 citations indexed

About

Roberto De Luca is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Roberto De Luca has authored 32 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Radiology, Nuclear Medicine and Imaging, 22 papers in Oncology and 17 papers in Immunology. Recurrent topics in Roberto De Luca's work include Monoclonal and Polyclonal Antibodies Research (23 papers), CAR-T cell therapy research (17 papers) and Immunotherapy and Immune Responses (11 papers). Roberto De Luca is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (23 papers), CAR-T cell therapy research (17 papers) and Immunotherapy and Immune Responses (11 papers). Roberto De Luca collaborates with scholars based in Switzerland, Italy and United Kingdom. Roberto De Luca's co-authors include Dario Neri, Samuele Cazzamalli, Francesca Pretto, Jörg Scheuermann, Yizhou Li, Alessandra Villa, Markus G. Manz, Christian Pellegrino, Tobias Weiß and Giovanni Pellegrini and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Nature Chemistry.

In The Last Decade

Roberto De Luca

31 papers receiving 459 citations

Peers

Countries citing papers authored by Roberto De Luca

Since Specialization

Citations

This map shows the geographic impact of Roberto De Luca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto De Luca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto De Luca more than expected).

Fields of papers citing papers by Roberto De Luca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto De Luca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto De Luca. The network helps show where Roberto De Luca may publish in the future.

Co-authorship network of co-authors of Roberto De Luca

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto De Luca. A scholar is included among the top collaborators of Roberto De Luca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto De Luca. Roberto De Luca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer 2024 ·Molecular Cancer Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Christian Pellegrino, Sheila Dakhel Plaza, Roberto De Luca, Markus G. Manz, Annette Oxenius, Emanuele Puca, Cornelia Halin, Dario Neri	1
2	A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors 2024 ·EMBO Molecular Medicine ·(unknown), Ettore Gilardoni, (unknown), Jacqueline Mock, Frauke Seehusen, (unknown), Emanuele Puca, Roberto De Luca, Christian Pellegrino, Thomas Look, Tobias Weiß, Markus G. Manz, Cornelia Halin, Dario Neri, Sheila Dakhel Plaza	4
3	Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy 2024 ·OncoTargets and Therapy ·(unknown), Dario Neri, Roberto De Luca	4
4	DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target 2024 ·Chemical Science ·(unknown), Sebastian Oehler, Tony Georgiev, Marco Müller, (unknown), Roberto De Luca, Nicholas Favalli, Dario Neri, Samuele Cazzamalli, (unknown)	2
5	Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells 2024 ·Leukemia ·(unknown), Renier Myburgh, Christian Pellegrino, Christian Koch, (unknown), Francesco Manfredi, (unknown), (unknown), Florin Schneiter, (unknown), (unknown), Roberto De Luca, Nicholas Favalli, Chiara F. Magnani, Timm Schroeder, Dario Neri, Markus G. Manz	5
6	Tripokin: A multi‐specific immunocytokine for cancer immunotherapy 2024 ·International Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Michael Weller, Christian Pellegrino, Markus G. Manz, (unknown), Roberto De Luca	1
7	An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Ettore Gilardoni, Thomas Look, Miaomiao Sun, (unknown), Vlad Moisoiu, Christian Pellegrino, Markus G. Manz, Emanuele Puca, Michael Weller, Tobias Weiß, (unknown), Roberto De Luca	1
8	Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology 2023 ·SHILAP Revista de lepidopterología ·(unknown), Mattia Pedotti, (unknown), Luca Simonelli, Raoul De Gasparo, (unknown), (unknown), (unknown), Mattia Matasci, Roberto De Luca, Irene Cassaniti, Josè Camilla Sammartino, Antonio Piralla, Fausto Baldanti, Dario Neri, Luca Varani	3
9	Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma 2023 ·Science Translational Medicine ·Thomas Look, Emanuele Puca, (unknown), Daniel S. Kirschenbaum, Roberto De Luca, Riccardo Stucchi, (unknown), (unknown), Patrick Roth, Yonatan Katzenelenbogen, Assaf Weiner, Lukas Rindlisbacher, Burkhard Becher, Ido Amit, Michael Weller, Dario Neri, Teresa Hemmerle, Tobias Weiß	24
10	Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen 2023 ·mAbs ·(unknown), (unknown), (unknown), (unknown), (unknown), Sheila Dakhel Plaza, Alessandra Villa, Emanuele Puca, Roberto De Luca, Annette Oxenius, Dario Neri	5
11	Abstract 1877: Tripokin: potential best-in-class for tumor targeted interleukin-2 (IL2) potentiated by tumor necrosis factor (TNF) 2023 ·Cancer Research ·(unknown), (unknown), Mattia Matasci, Dario Neri, Roberto De Luca	1
12	An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions 2023 ·Antibodies ·(unknown), (unknown), Ettore Gilardoni, (unknown), Emanuele Puca, Dario Neri, Roberto De Luca	4
13	Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21 2022 ·Antibodies ·(unknown), Dario Neri, Tobias Weiß, Michael Weller, Roberto De Luca	7
14	Publisher Correction: Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications 2021 ·Nature Chemistry ·Nicholas Favalli, Gabriele Bassi, Christian Pellegrino, Jacopo Millul, Roberto De Luca, Samuele Cazzamalli, Su Yang, Anika Trenner, (unknown), Renier Myburgh, (unknown), Stuart J. Conway, Alessandro A. Sartori, Markus G. Manz, Richard A. Lerner, Peter K. Vogt, Jörg Scheuermann, Dario Neri	1
15	Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications 2021 ·Nature Chemistry ·Nicholas Favalli, Gabriele Bassi, Christian Pellegrino, Jacopo Millul, Roberto De Luca, Samuele Cazzamalli, Su Yang, Anika Trenner, (unknown), Renier Myburgh, (unknown), Stuart J. Conway, Alessandro A. Sartori, Markus G. Manz, Richard A. Lerner, Peter K. Vogt, Jörg Scheuermann, Dario Neri	54
16	A Novel Antibody–IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis 2021 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Jacqueline Mock, (unknown), Alessandra Villa, Dario Neri, Roberto De Luca	19
17	Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo 2020 ·mAbs ·(unknown), (unknown), Alessandra Villa, Tobias Weiß, Michael Weller, Dario Neri, Roberto De Luca	14
18	A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas 2019 ·Frontiers in Oncology ·Roberto De Luca, (unknown), (unknown), Alessandra Villa, (unknown), Alessandro Sannino, (unknown), (unknown), (unknown), Dario Neri	13
19	Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold 2018 ·Nature Chemistry ·Yizhou Li, Roberto De Luca, Samuele Cazzamalli, Francesca Pretto, (unknown), Jörg Scheuermann, Dario Neri	115
20	Potency-matched Dual Cytokine–Antibody Fusion Proteins for Cancer Therapy 2017 ·Molecular Cancer Therapeutics ·Roberto De Luca, Alex Soltermann, Francesca Pretto, (unknown), Giovanni Pellegrini, Sarah Wulhfard, Dario Neri	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact